Moderna
Moderna is the mRNA company whose personalised cancer vaccine intismeran won the first phase 3 in the class (August 2026).
Intismeran autogene (with Merck), mRNA-4359 (shared antigen), in vivo CAR and immuno-oncology mRNA programmes.
Pages like this
not linked directly; found by shared links- CompanyBioNTech
Shares Self-amplifying and circular RNA therapeutics, Vaccines aimed only at mutations shared by every tumour cell, Personalised cancer vaccines at commodity cost through fully automated manufacturing, Personalised vaccines given only when the blood test turns positive.
- TrialINTerpath-001 (V940-001)
Shares Vaccines aimed only at mutations shared by every tumour cell, KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery, Intismeran autogene, Personalised neoantigen (mRNA) vaccines.
- CompanyOrna Therapeutics (Eli Lilly)
Shares Instruct tumour cells to make antibodies against their own oncoprotein, mRNA-delivered MYC decoy proteins instead of MYC inhibitors, Self-amplifying and circular RNA therapeutics.
- ProductAutogene cevumeran
Shares Personalised cancer vaccines at commodity cost through fully automated manufacturing, Personalised vaccines given only when the blood test turns positive, Personalised neoantigen (mRNA) vaccines, Cold tumours and the immunosuppressive microenvironment.
- TermNeoantigen
Shares Vaccines aimed only at mutations shared by every tumour cell, Personalised cancer vaccines at commodity cost through fully automated manufacturing, Personalised vaccines given only when the blood test turns positive, KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery.
- Key paperRojas 2023: a personalised mRNA vaccine trained T cells against each patient's pancreatic cancer, and those who responded stayed cancer-free longer
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Cold tumours and the immunosuppressive microenvironment, Melanoma.
- PairingPersonalised neoantigen vaccine + PD-1 blockade
Shares Intismeran autogene, Personalised neoantigen (mRNA) vaccines, Melanoma.
- PersonRyan J. Sullivan
Shares KEYNOTE-942: a personalised mRNA cancer vaccine plus pembrolizumab after melanoma surgery, Melanoma.